Mylan MYL

  1. All
  2. Commentary
  3. Stock Reports
  4. ETF Reports
  5. Headlines
    1. Teva denied injunction

      Headlines

      Sat, 19 Apr 2014

      The U.S. Supreme Court Chief Justice John Roberts denies Teva's ( TEVA ) application for an injunction to prevent Mylan ( MYL ) from launching a generic version of Copaxone until the Court rules on the matter later this year. The ruling opens

    2. Mylan launches generic transdermal contraceptive

      Headlines

      Thu, 17 Apr 2014

      Transdermal System 150/35 mcg/day) $150M U.S. sales, Mylan ( MYL ) launches its generic equivalent XULANE . The product ..... a method of contraception. According to IMS Health, Mylan has 300 ANDAs pending FDA approval representing $104

    3. Smead Capital Management Shareholder Letter 1Q 2014

      Headlines

      Wed, 16 Apr 2014

      were names like Walgreen, Merck and Mylan . This represents a popularity associated ..... We sold the last of our stake in Mylan during the quarter as enthusiasm for it became ..... changes included selling the last of Mylan and the last of Bristol-Myers Squibb

    4. IBB iShares Nasdaq Biotechnology ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Wed, 16 Apr 2014

      in biotechnology. The remaining 21.5% of assets are invested in small- and mid-cap pharmaceutical firms such as Mylan MYL , Salix SLXP, and Theravance THRX; the U.S.' largest pharmaceutical firms trade on the New York Stock Exchange

    5. Generics want to go after Copaxone now

      Headlines

      Tue, 15 Apr 2014

      Two teams of generic Copaxone makers, Sandoz/Momenta and Mylan /Natco ask the U.S. Supreme Court to allow a lower court ruling ..... A ruling on the case might not happen until mid-2015. ( NVS ) ( MYL ) ( MNTA ) Post your comment!

    6. Court forces settlement in FROVA patent case

      Headlines

      Fri, 11 Apr 2014

      district court forces a settlement in the patent case between Mylan ( MYL ) and Endo Pharmaceuticals ( ENDP ) over the migraine ..... 28, 2014 decision in favor of Endo paving the way for Mylan to launch its generic version after FDA approval instead

    7. Celgene In Mylan's Cross-Hairs: "I'm Shakin' In My Boots"... Well, Maybe A Little

      Headlines

      Mon, 7 Apr 2014

      and perhaps alarming some investors is Mylan ( MYL ) is suing Celgene for exercising its patents rights. Mylan is accusing Celgene of "using federal ..... the headline, frankly I was annoyed. Mylan not only wants mass quantities of Revlimid

    8. Sun Acquires Struggling Ranbaxy at Half the Price Daichii Paid for a Controlling Stake in 2008

      Commentary

      Mon, 7 Apr 2014

      targeted by Sun's management. The combined entity will possess the most market share in the Indian generic pharmaceutical space, and make it the fifth-largest generic drug manufacturer in the world behind Teva, Sandoz, Actavis, and Mylan .

    9. UPDATE 4-Swedish drugmaker Meda spurns Mylan takeover approach

      Headlines

      Fri, 4 Apr 2014

      (Adds Meda shares, Mylan comment, valuation detail, quote)

    10. BRIEF-Meda shares surge after says spurns Mylan takeover approach

      Headlines

      Fri, 4 Apr 2014

      STOCKHOLM, April 4 (Reuters) - Meda : * Shares rise 11 percent in resumed trading after says rejects Mylan

    « Prev12345Next »
    Content Partners